Alopecia Areata | Alopecia Areata Registry
Alopecia Areata research study
What is the primary objective of this study?
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia areata.
Who is eligible to participate?
Inclusion Criteria - Diagnosed with alopecia areata by a dermatologist - United States resident Accepts Health Volunteers: Non blood-related individuals who are unaffected with alopecia areata and do not live in the same household with alopecia areata patient.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Autoimmune Hair Loss
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Active, not recruiting
Start Date: November 2001
Completed Date: November 2099
Primary Outcome: Alopecia Areata Registry
Study sponsors, principal investigator, and references
Principal Investigator: Madeleine Duvic, MD
Lead Sponsor: M.D. Anderson Cancer Center
Collaborator: National Alopecia Areata Foundation
Duvic M, Norris D, Christiano A, Hordinsky M, Price V. Alopecia areata registry: an overview. J Investig Dermatol Symp Proc. 2003 Oct;8(2):219-21. Review.
Barahmani N, Yang Y, Lopez A, Duvic M. Atopic alopecia areata patients have increased serum Th1 Cytokine profiles. 66th Annual meeting of Society for Investigative Dermatology. St.Louis, MO, May 2005. JID 124 (4): A100, 2005.
Breuer-McHam J, Hunzicker K, Barahmani N, Zhang Q, Babu D, Christiano A, Hordinsky M, Norris D, Price V, Duvic, M. Epidemiologic and disease associations in participants of the national alopecia areata (NAAR) registrants. Accepted by Society for Investigational Dermatology, April 12, 2004. JID 122 (3): A107, 2004.
de Andrade M, Barahmani N, Hunzicker K, Zhang Q, Joan Breuer- McHam, Joyce Osei, Daniel Babu, Qingyi Wei, Reveille J, Duvic M. HLA Class II associations confirm alopecia areata phenotypic subsets. 66th Annual meeting of Society for Investigative Dermatology. St. Louis, MO, May 2005.JID 124 (4): A107, 2005.
Barahmani N, de Andrade M, Slusser JP, Wei Q, Hordinsky M, Price VH, Christiano A, Norris D, Reveille J, Duvic M. Human leukocyte antigen class II alleles are associated with risk of alopecia areata. J Invest Dermatol. 2008 Jan;128(1):240-3. Epub 2007 Jul 19.
Ahmed AM, Barahmani N, Duvic M; National Alopecia Areata Registry. Familial alopecia areata and chronic thrombocytopenia. J Am Acad Dermatol. 2008 May;58(5 Suppl 1):S75-7. doi: 10.1016/j.jaad.2007.05.017.
Rodriguez TA, Duvic M; National Alopecia Areata Registry. Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol. 2008 Jul;59(1):137-9. doi: 10.1016/j.jaad.2008.02.005. Epub 2008 Mar 7.
Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007 Feb;80(2):316-28. Epub 2007 Jan 5.
Barahmani N, de Andrade M, Slusser JP, Zhang Q, Duvic M. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006 Jan;126(1):74-8.